Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 4,802 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance

NCT00305097
View directory record Official record
Conditions
Overweight
Interventions
Decaffeinated coffee, Caffeinated coffee, No coffee
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 23, 2026, 4:19 AM EDT
Active, not recruiting No phase listed Observational

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

NCT00568997
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 3 Interventional

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

NCT02601703
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tacrolimus Ointment 0.1%, Protopic® ointment, 0.1%, Placebo of Tacrolimus Ointment
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Tempe, Arizona • Anaheim, California • Bell Gardens, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 23, 2026, 4:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

NCT07277660
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Galvokimig, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Oceanside, California • Santa Monica, California • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT02584959
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
C1 esterase inhibitor [human] liquid, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 23, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Adalimumab in Progressive Sarcoidosis

NCT00311246
View directory record Official record
Conditions
Sarcoidosis
Interventions
Adalimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice

NCT01979588
View directory record Official record
Conditions
Influenza Like Illness, Asthma, Group A Streptococcal Infection, Pertussis
Interventions
What's Going Around tool, Control
Other
Lead sponsor
Endeavor Health
Other
Eligibility
Not listed
Enrollment
206,703 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 23, 2026, 4:19 AM EDT
Withdrawn Phase 4 Interventional

Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain

NCT02569073
View directory record Official record
Conditions
Esophageal Diseases
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 23, 2026, 4:19 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Pilot Study of Magnesium Infusions in Pediatric Asthma

NCT01522040
View directory record Official record
Conditions
Asthma
Interventions
Magnesium Sulfate, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Subcutaneous Immunotherapy for Mouse in Adults

NCT02532179
View directory record Official record
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
Mouse Allergenic Extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 23, 2026, 4:19 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

NCT07869043
View directory record Official record
Conditions
Asthma
Interventions
tilrekimig, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Austin, Texas • Tomball, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

NCT05121480
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
27
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 23, 2026, 4:19 AM EDT
Completed No phase listed Observational

To Determine the Validity of the ACT in an Adolescent Population With Persistent Asthma

NCT02662413
View directory record Official record
Conditions
Asthma
Interventions
Validation of Asthma Control Questionnaire
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 23, 2026, 4:19 AM EDT
Completed No phase listed Observational

An Observational Study of the Use and Safety of Xolair® During Pregnancy

NCT00373061
View directory record Official record
Conditions
Asthma
Interventions
Xolair®
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Not applicable Interventional Results available

Improving Asthma Care by Partnering With School Nurses to Bring Asthma Care Into the Inner-City Schools

NCT02735174
View directory record Official record
Conditions
Asthma
Interventions
Sensor cap system for inhalers, App for SmartPhone, Motivational interviews, Telehealth clinic visits
Device · Other · Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 23, 2026, 4:19 AM EDT
Completed No phase listed Observational

Acute MI UDMI Staging Diagnosis by High-sensitivity Cardiac Troponin-I

NCT07163988
View directory record Official record
Conditions
Acute Myocardial Infarction (AMI)
Interventions
Not listed
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years to 79 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed No phase listed Observational

Detection of Aggressive Breast Tumors Using Tc-99m-NC100692

NCT00888589
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Michael O'Connor
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 23, 2026, 4:19 AM EDT
Active, not recruiting Phase 4 Interventional

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689
View directory record Official record
Conditions
Asthma
Interventions
Albuterol and budesonide inhalation aerosol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

NCT01122680
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Not applicable Interventional Results available

How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment

NCT00595361
View directory record Official record
Conditions
Asthma
Interventions
salmeterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT01753739
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 23, 2026, 4:19 AM EDT
Completed No phase listed Observational

GRANITE: Airsupra Effectiveness in the Real World

NCT07141277
View directory record Official record
Conditions
Asthma
Interventions
None (Observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
4,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

NCT01842607
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Long Beach, California • Newport Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 23, 2026, 4:19 AM EDT